Market Place
Sourcing Support
Alladapt Immunotherapeutics Receives FDA Fast Track Designation for ADP101
22 Nov 2023 //
GLOBENEWSWIRE
Alladapt Immunotherapeutics Presents Phase 1/2 Harmony Data of ADP101
09 Nov 2023 //
GLOBENEWSWIRE
Alladapt touts data on food allergy drug as it preps for PhIII
13 Jun 2023 //
ENDPTS
Alladapt Announces Data from Phase 1/2 Harmony Study Evaluating ADP101
13 Jun 2023 //
GLOBENEWSWIRE
Alladapt Announces Presentations at European Academy of (EAACI) Congress 2023
16 May 2023 //
GLOBENEWSWIRE
Alladapt Appoints Louise Peacock as Chief Regulatory Affairs and Quality Officer
01 May 2023 //
GLOBENEWSWIRE
Alladapt to Present at the 41st Annual J.P. Morgan Healthcare Conference
04 Jan 2023 //
GLOBENEWSWIRE
Alladapt to Participate in Citi`s 17th Annual BioPharma Conference
31 Aug 2022 //
GLOBENEWSWIRE
Alladapt Announces Loan Agreement with Hercules Capital
30 Aug 2022 //
GLOBENEWSWIRE
Alladapt banks $119M to push allergy therapy through trials
22 Jun 2022 //
FIERCEBIOTECH
Alladapt Completes Oversubscribed $119 Million Institutional Financing
22 Jun 2022 //
GLOBENEWSWIRE
Alladapt Initiates Encore Open-Label Extension Study for Phase 1/2 of ADP101
17 Mar 2022 //
GLOBENEWSWIRE
Alladapt starts work on immunotherapy plant near Philadelphia
20 Aug 2021 //
FIERCEPHARMA
Alladapt to buid New Manufacturing Facility for Production of Immunotherapeutics
19 Aug 2021 //
GLOBENEWSWIRE
Alladapt Appoints Glenn Reicin as Chief Financial Officer
22 Jun 2021 //
GLOBENEWSWIRE
Alladapt Commences Phase 1/2 Clinical Trial in Food Allergy
22 Apr 2021 //
GLOBENEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.